Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/16/?d=1Neue Studien: Europe PMCdeAssociation Between Alcohol Consumption and Psoriasis: Exploratory Analysis of Crowdsourced Web Search Data in Sweden.https://www.psoriasis-news.de/articles.html/1_articles/association-between-alcohol-consumption-and-psoriasis-exploratory-analysis-of-crowdsourced-web-search-data-in-sweden-r240/BackgroundThe nature of the relationship between psoriasis and alcohol consumption has been the topic of discussion for many years. Some studies have found that a higher intake of alcohol may be associated with a more severe manifestation of the disease. At the same time, patients with psoriasis often demonstrate elevated levels of alcohol consumption. It has not yet been fully established whether alcohol abuse serves as a trigger for psoriasis or if patients with psoriasis are simultaneously more prone to alcohol abuse.

Objective

The objective of this study was to employ Google Trends as a tool for crowdsourcing data on a national level to explore the relationship between psoriasis and the consumption of alcohol in Sweden.

Methods

This study examines crowdsourced web search data related to psoriasis and other skin disease-related search terms (such as utslag [rash]) as well as search interest in different types of alcohol. The analysis covers a 5-year period from 2018 to 2023 in Sweden, focusing on search behavior and correlations across this period.

Results

The search behavior regarding psoriasis and alcohol-related search terms showed seasonal variations throughout the year. The relative search volume for psoriasis peaked in February, while alcohol-related searches, particularly Systembolaget and vodka, peaked in December and June. Our statistical analysis revealed relationships between the search interest regarding psoriasis and terms related to alcohol consumption, with disparities between different types of alcohol. The term "psoriasis" was negatively correlated with "Systembolaget" (r=-0.210), "vitt vin" (r=-0.224), and "vodka" (r=-0.220) (all P<.001), while the term "utslag" showed positive correlations with these same alcohol-related terms (r=0.278-0.347; P<.001).

Conclusions

Crowdsourced data can offer valuable insights into population-level behavior. The observed negative correlations between psoriasis and alcohol-related searches suggest complex interactions, possibly reflecting reduced disease awareness or care during periods of higher alcohol consumption. The direction and strength of the correlations with psoriasis were not consistent across the different types of alcohol investigated in this study, which poses the question whether the relationship might be influenced by the type of beverage consumed. Further research is warranted to explore underlying mechanisms and validate these findings in clinical populations.

Weiterlesen

]]>240Thu, 04 Sep 2025 18:54:24 +0000Smilax glabra Roxb. extract alleviates psoriasis-like lesions in mice by the synergistic effects of TOP2A inhibition and AhR activation.https://www.psoriasis-news.de/articles.html/1_articles/smilax-glabra-roxb-extract-alleviates-psoriasis-like-lesions-in-mice-by-the-synergistic-effects-of-top2a-inhibition-and-ahr-activation-r239/Weiterlesen

]]>239Thu, 04 Sep 2025 18:54:24 +0000Epidemiology of Hypertension in Psoriasis: An Analysis of Trends from 2006 to 2023.https://www.psoriasis-news.de/articles.html/1_articles/epidemiology-of-hypertension-in-psoriasis-an-analysis-of-trends-from-2006-to-2023-r238/Weiterlesen

]]>238Thu, 04 Sep 2025 18:54:24 +0000Patient Experiences with Psoriatic Disease in the USA: Results from the Psoriasis and Beyond Global Study.https://www.psoriasis-news.de/articles.html/1_articles/patient-experiences-with-psoriatic-disease-in-the-usa-results-from-the-psoriasis-and-beyond-global-study-r237/BackgroundPsoriatic disease (PsD) is a chronic, multisystem, inflammatory disorder encompassing psoriasis, psoriatic arthritis (PsA), and their associated comorbidities.

Objective

The aim of this subanalysis of the global "Psoriasis and Beyond" study was to evaluate patients' experiences of living with PsD in the USA.

Methods

The study included a cross-sectional, quantitative, 25-min online survey of adults with self-reported, healthcare professional-diagnosed, moderate-to-severe psoriasis, with or without PsA. USA-based patients were recruited through online panels by the Institut de Publique Sondage D'Opinion Secteur and The National Psoriasis Foundation.

Results

This analysis included 793 US patients with psoriasis; 43% also had PsA. Overall, 75% of patients knew that their disease was systemic, and 65% had heard the term "psoriatic disease." Of patients without diagnosed PsA, 50% screened positive for PsA using the Psoriasis Epidemiology Screening Tool. Psoriasis negatively affected emotional well-being and quality of life (QoL) in the majority of patients (87% and 91%, respectively). Overall, 29% of patients reported that they could not work or study in the week prior to the survey; of these, 98% responded that psoriasis had a very or extremely large impact on their QoL. Mean diagnostic delays of 3.7 and 3.3 years for psoriasis and PsA, respectively, were reported.

Conclusions

This analysis of USA-based patients with PsD highlights the profound impact of PsD on emotional well-being and QoL and suggests potential underdiagnosis of PsA. There is a need to ensure early PsD diagnosis and to provide holistic treatment, including mental health support.

Weiterlesen

]]>237Thu, 04 Sep 2025 18:54:24 +0000Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients with Psoriatic Arthritis.https://www.psoriasis-news.de/articles.html/1_articles/incidence-and-predictors-of-secondary-failure-to-biologic-therapy-in-patients-with-psoriatic-arthritis-r236/ObjectiveSecondary failure to biologic DMARDs (bDMARDs) is challenging and contributes to the complexity of managing psoriatic arthritis (PsA). We aimed to define the frequency and incidence of this phenomenon in PsA and identify the risk factors for its occurrence.

Methods

We retrieved data on PsA patients from our single-centre, specialized-care, prospective observational cohort who initiated and remained on bDMARDs for ≥1 year after clinic enrollment between 2000 and 2023. We defined response to therapy at the one-year visit (baseline) as achievement of ≥40% reduction in the swollen joint count (SJC) and either ≥50% reduction in PASI or PASI ≤2. We defined secondary failure as the inability to maintain response criteria or as the clinician's judgment of loss of effectiveness. To examine factors associated with secondary failure, we fitted Cox regression models.

Results

Of 482 patients included in the study, 264 (54.8%) were responders at one year. Of these, 94 (35.6%) developed secondary failure at a median of 1.6 [IQR: 0.7, 3.8] years from response. In the multivariable model, higher SJC (HR 1.39, 95% CI 1.05-1.84) and PASI (HR 1.14, 95% CI 1.01-1.29) at baseline were associated with secondary failure. TNFi vs. other bDMARD use (HR 0.39, 95% CI 0.18-0.88), initiation as first-line bDMARD (HR 0.48, 95% CI 0.25-0.91), and treatment initiation during more recent calendar years (HR 0.34, 95% CI 0.12-0.98) were associated with less secondary failure.

Conclusion

Secondary failure to bDMARDs is common in PsA and may be influenced by both disease- and therapy-related factors.

Weiterlesen

]]>236Thu, 04 Sep 2025 18:54:24 +0000GLP-1RA and reduced mortality, cardiovascular and psychiatric risks in psoriasis: a large-scale cohort study.https://www.psoriasis-news.de/articles.html/1_articles/glp-1ra-and-reduced-mortality-cardiovascular-and-psychiatric-risks-in-psoriasis-a-large-scale-cohort-study-r235/BackgroundPsoriasis is associated with a significant comorbidity burden, especially cardiovascular and metabolic complications. Glucagon-like peptide-1 receptor agonists (GLP-1RA), such as semaglutide, used to treat obesity and diabetes, could potentially reduce comorbidity in patients with psoriasis.

Objective

To investigate all-cause mortality, cardiovascular, inflammatory, psychiatric outcomes, and adverse events in psoriasis patients treated with GLP-1RA.

Methods

This retrospective population-based cohort study utilized real-world data from the US TriNetX database. Patients with psoriasis who were treated for diabetes or obesity with GLP-1RA during the full follow-up period of 2 years were compared with those treated with other systemic anti-diabetic or obesity drugs. After 1:1 propensity-score matching for relevant risk factors, 3,048 participants were included in each cohort. The primary outcomes included the risk of cardiometabolic, psychiatric, and autoimmune sequelae of psoriasis, as well as all-cause mortality and potential adverse drug events. The analysis was repeated using cohorts without psoriasis and results were further validated through two sensitivity analyses involving (i) later follow-up periods, or (ii) exclusion of patients with pustular psoriasis.

Results

In the matched cohorts of 3,048 patients with psoriasis treated with GLP-1RA (60.37% females, mean age 56.94 years, standard deviation [SD] 12.02 years) versus other antidiabetic and obesity drugs (61.91% females, mean age 56.42 years, SD 14.16 years), GLP-1RA treatment was associated with significantly decreased all-cause mortality (hazard ratio [HR] 0.219, 95% confidence interval [CI] 0.123-0.391, p<0.0001) and reduced risk for major adverse cardiac events (MACE, HR 0.561, 95% CI 0.442-0.714, p<0.0001). Additionally, lower risks for alcohol (HR 0.346, CI 0.174-0.685, p=0.009) and substance abuse (HR 0.510, CI 0.350-0.743, p=0.002) were observed. Typical adverse drug events were not more frequent in the GLP-1RA cohort. The risk reductions were more pronounced in the cohorts with psoriasis compared to persons with obesity or diabetes without psoriasis. Findings were consistent across all sensitivity analyses.

Conclusions

GLP-1RA treatment was safe and associated with reduced risks of cardiovascular and psychiatric comorbidities, as well as lower mortality in patients with psoriasis, with risk reductions markedly higher than in cohorts without psoriasis. Physicians should consider this drug class for patients with psoriasis and comorbid obesity or diabetes.

Weiterlesen

]]>235Thu, 04 Sep 2025 18:54:24 +0000Platelet Activation and a Platelet Biosignature Are Associated With Cardiovascular Risk in Patients With Controlled Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/platelet-activation-and-a-platelet-biosignature-are-associated-with-cardiovascular-risk-in-patients-with-controlled-psoriasis-r234/Weiterlesen

]]>234Thu, 04 Sep 2025 18:54:24 +0000Does ultrasound detect joint and intestinal changes in psoriatic arthritis and ulcerative colitis after immunobiological treatment: A case reporthttps://www.psoriasis-news.de/articles.html/1_articles/does-ultrasound-detect-joint-and-intestinal-changes-in-psoriatic-arthritis-and-ulcerative-colitis-after-immunobiological-treatment-a-case-report-r233/No abstract supplied.

Weiterlesen

]]>233Wed, 03 Sep 2025 07:11:26 +0000Leveraging Pixel-wise Embeddings for Segmenting Psoriasis Lesion Areashttps://www.psoriasis-news.de/articles.html/1_articles/leveraging-pixel-wise-embeddings-for-segmenting-psoriasis-lesion-areas-r232/In the context of psoriasis lesion segmentation, traditional methods in image segmentation, including region-based approaches like Mask R-CNN, have shown notable success. However, the problem of segmenting irregular and intricate biological structures such as psoriasis lesions presents significant challenges that cannot be effectively captured by standard bounding box approximations. This paper explores the potential of transforming psoriasis lesion segmentation into pixel labeling tasks, which promise greater efficiency and integration with modern image-to-image networks widely used across various domains. We investigate the limitations of convolutional-based architectures in generating dense pixel embeddings capable of distinguishing individual lesions. Through both theoretical analysis and empirical evidence, we propose a novel approach that leverages semi-convolutional operations. These modifications, which introduce spatially guided pixel embeddings, offer substantial improvements over traditional methods and demonstrate their applicability to the segmentation of complex biological forms. By drawing connections to advanced techniques such as Hough voting and bilateral kernels steered by convolutional networks, we show that these methods significantly enhance the segmentation accuracy of psoriasis lesions, outperforming conventional region-based models like Mask R-CNN in terms of precision and adaptability to irregular shapes.

Weiterlesen

]]>232Wed, 03 Sep 2025 07:11:26 +0000The role of psychological stress in the pathogenesis of psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/the-role-of-psychological-stress-in-the-pathogenesis-of-psoriasis-r231/Weiterlesen

]]>231Wed, 03 Sep 2025 07:11:26 +0000Development and Validation of an Artificial Intelligence-Driven Model for Accurate Classification of Erythrodermic Psoriasis Severity: Erythrodermic Psoriasis Integrated Classification System (EPICS).https://www.psoriasis-news.de/articles.html/1_articles/development-and-validation-of-an-artificial-intelligence-driven-model-for-accurate-classification-of-erythrodermic-psoriasis-severity-erythrodermic-psoriasis-integrated-classification-system-epics-r230/Weiterlesen

]]>230Wed, 03 Sep 2025 07:11:26 +0000Biosimilars for the Treatment of Moderate to Severe Chronic Plaque Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/biosimilars-for-the-treatment-of-moderate-to-severe-chronic-plaque-psoriasis-r229/Weiterlesen

]]>229Wed, 03 Sep 2025 07:11:26 +0000What Is the Diagnostic Capacity of Existing Severity Scoring Tools for Nail Psoriasis?https://www.psoriasis-news.de/articles.html/1_articles/what-is-the-diagnostic-capacity-of-existing-severity-scoring-tools-for-nail-psoriasis-r228/Weiterlesen

]]>228Wed, 03 Sep 2025 07:11:26 +0000Mitochondrial sirtuins 3, 4 and 5 in patients with psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/mitochondrial-sirtuins-3-4-and-5-in-patients-with-psoriasis-r227/Weiterlesen

]]>227Wed, 03 Sep 2025 07:11:26 +0000Successful guselkumab treatment for a psoriasis patient experiencing an adrenal crisis: a case report.https://www.psoriasis-news.de/articles.html/1_articles/successful-guselkumab-treatment-for-a-psoriasis-patient-experiencing-an-adrenal-crisis-a-case-report-r226/Weiterlesen

]]>226Wed, 03 Sep 2025 06:53:32 +0000The Skin-Brain Axis in Psoriasis and Depression: Roles of Inflammation, Hormones, Neuroendocrine Pathways, Neuropeptides, and the Microbiome.https://www.psoriasis-news.de/articles.html/1_articles/the-skin-brain-axis-in-psoriasis-and-depression-roles-of-inflammation-hormones-neuroendocrine-pathways-neuropeptides-and-the-microbiome-r225/Weiterlesen

]]>225Wed, 03 Sep 2025 06:53:32 +0000Toward Harmonized Recommendations for Psoriatic Arthritis: A Comparative Viewpoint on Global Guidelines.https://www.psoriasis-news.de/articles.html/1_articles/toward-harmonized-recommendations-for-psoriatic-arthritis-a-comparative-viewpoint-on-global-guidelines-r224/ObjectivePsoriatic arthritis (PsA) guidelines aim to provide consistent, evidence-based recommendations. Multiple regional guidelines exist, often based on similar evidence but with different methodologies and contexts. Our aim was to compare recent PsA treatment guidelines from the American College of Rheumatology, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, European Alliance of Associations for Rheumatology, and Pan American League of Associations for Rheumatology, identifying similarities, differences, and opportunities for global harmonization with regional adaptation.

Methods

Narrative comparative review of guideline documents published between 2018 and 2024 by major rheumatology societies was performed. Data on methodology, panel composition, treatment domains, pharmacologic recommendations, and update strategies were extracted and synthesized.

Results

Guidelines share core principles, including domain-based approaches, treat-to-target strategies, and the use of conventional synthetic disease-modifying antirheumatic drugs and biologics. Differences arise from methodological frameworks (eg, GRADE [Grading of Recommendations Assessment, Development, and Evaluation], domain-based, adolopment), stakeholder composition, and explicit consideration of regional drug access.

Conclusion

A hybrid framework combining global core recommendations with modular regional adaptations may optimize resource use, improve guideline sustainability, and maintain local relevance. Living systematic reviews and artificial intelligence could support more timely updates.

Weiterlesen

]]>224Wed, 03 Sep 2025 06:53:32 +0000Long-term Safety and Efficacy of Ixekizumab in Patients With Moderate to Severe Psoriasis – a Systematic Review of Randomised Controlled Trialshttps://www.psoriasis-news.de/articles.html/1_articles/long-term-safety-and-efficacy-of-ixekizumab-in-patients-with-moderate-to-severe-psoriasis-a-systematic-review-of-randomised-controlled-trials-r223/Background This systematic review evaluates the efficacy, safety, and tolerability of ixekizumab (IXE), an anti-IL 17A monoclonal antibody, in treating moderate to severe psoriasis. Methods A comprehensive search of PubMed and Scopus using the terms ‘ixekizumab’ and ‘psoriasis’ was conducted. This study was registered in PROSPERO (CRD42024539975) and followed the PRISMA guidelines for reporting systematic reviews. Inclusion criteria encompassed randomised clinical trials assessing the efficacy and safety/tolerability of ixekizumab for moderate-to-severe psoriasis, published from inception until April 2024. Case reports, conference papers, and observational studies were excluded. A total of 5 studies (6 randomised controlled trials) with 4705 participants met the selection criteria out of 1172 search results. The risk of bias was assessed among the selected studies using the RoBViS tool. Results The standardised dosing regimen of ixekizumab demonstrated superior efficacy compared to placebo in improving Psoriasis Area and Severity Index (PASI) from baseline and Static Physician Global Assessment (sPGA) across most of the included studies. No significant difference in efficacy was observed when comparing ixekizumab with ustekinumab in a survey conducted by Reich et al. Most adverse events were mild, although some serious ones were reported. Conclusion Ixekizumab, a monoclonal antibody approved for treating moderate to severe psoriasis, exhibits a superior safety profile comparable to other biologics used in psoriasis. However, its widespread usage in psoriasis is still relatively less than conventional non-selective immunomodulatory agents.

Weiterlesen

]]>223Wed, 03 Sep 2025 06:53:32 +0000Relative sensitivity and preference of indicators in pharmaceutical trials of psoriasis and psoriatic arthritis.https://www.psoriasis-news.de/articles.html/1_articles/relative-sensitivity-and-preference-of-indicators-in-pharmaceutical-trials-of-psoriasis-and-psoriatic-arthritis-r222/Weiterlesen

]]>222Wed, 03 Sep 2025 06:53:32 +0000Trifolirhizin improves the hyperproliferation and excessive inflammatory response in human HaCaT keratinocytes and ameliorates skin lesions in psoriasis-like mouse models.https://www.psoriasis-news.de/articles.html/1_articles/trifolirhizin-improves-the-hyperproliferation-and-excessive-inflammatory-response-in-human-hacat-keratinocytes-and-ameliorates-skin-lesions-in-psoriasis-like-mouse-models-r221/Weiterlesen

]]>221Wed, 03 Sep 2025 06:53:32 +0000Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies.https://www.psoriasis-news.de/articles.html/1_articles/efficacy-of-risankizumab-across-grappa-domains-in-psoriatic-arthritis-a-pooled-analysis-of-patients-from-the-phase-3-keepsake-1-and-2-studies-r220/Weiterlesen

]]>220Wed, 03 Sep 2025 06:53:32 +0000Association Between Alcohol Consumption and Psoriasis: Exploratory Analysis of Crowdsourced Web Search Data in Sweden.https://www.psoriasis-news.de/articles.html/1_articles/association-between-alcohol-consumption-and-psoriasis-exploratory-analysis-of-crowdsourced-web-search-data-in-sweden-r219/Weiterlesen

]]>219Wed, 03 Sep 2025 06:53:32 +0000Validation of Turkish psoriatic arthritis screening tool for psoriatic arthritis: A cross-sectional comparative studyhttps://www.psoriasis-news.de/articles.html/1_articles/validation-of-turkish-psoriatic-arthritis-screening-tool-for-psoriatic-arthritis-a-cross-sectional-comparative-study-r218/No abstract supplied.

Weiterlesen

]]>218Wed, 03 Sep 2025 06:53:32 +0000Network pharmacology and Mendelian randomization analysis of Xiao Bi decoction in treating psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/network-pharmacology-and-mendelian-randomization-analysis-of-xiao-bi-decoction-in-treating-psoriasis-r217/No abstract supplied.

Weiterlesen

]]>217Wed, 03 Sep 2025 06:53:32 +0000Generalized Pustular Psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/generalized-pustular-psoriasis-r216/Weiterlesen

]]>216Sun, 24 Aug 2025 17:56:41 +0000